SomniTR provides support for patients with sleep.It is a delayed-release formula designed to initially release 1 mg of melatonin immediately after ingestion and 1 mg three hours later to help the patient stay asleep longer.*

SomniTR supports optimal melatonin production by supplementing multiple steps in the serotonin-to-melatonin pathway and also influences inhibitory GABAergic activity. The delayed–release melatonin in SomniTR provides sustained levels for up to eight hours. It also provides support for GABA-A receptor sites.

GABA-A agonists, such as Lactium have been shown to improve quality of sleep.* ForsLean supports cAMP while pantothenic acid supports acetyl coenzyme A, both of which are important in melatonin synthesis.*